VICTOZA LIRAGLUTIDE 1ML

About

Victoza (Liraglutide) 1ml is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus in adults and adolescents aged 10 years and older. It is used as an adjunct to diet and exercise to improve glycemic control. Liraglutide works by mimicking the effects of natural GLP-1, leading to glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon secretion, and slowing of gastric emptying. These actions collectively help to lower postprandial and fasting blood glucose levels. Additionally, Liraglutide has been shown to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Beyond its glucose-lowering effects, Liraglutide also promotes weight loss by increasing satiety and reducing appetite, making it a beneficial option for overweight or obese patients with type 2 diabetes. It is administered once daily, subcutaneously, and can be used as monotherapy or in combination with other antidiabetic agents, including basal insulin. Patients should be educated on proper injection technique, potential side effects, and the importance of lifestyle modifications. Close monitoring for gastrointestinal side effects, pancreatitis, and thyroid C-cell tumors (a risk identified in rodent studies) is crucial during treatment. Regular follow-up with a healthcare provider is essential to optimize therapy and ensure patient safety.

Uses

• Improvement of glycemic control in Type 2 Diabetes
• Reduction of major adverse cardiovascular events
• Aids in weight management for diabetic patients
• Used as an adjunct to diet and exercise

Directions For Use

Inject subcutaneously once daily, at any time of day, independent of meals. Rotate injection sites.

Benefits

• Effectively lowers blood glucose levels
• Reduces cardiovascular risk in certain patients
• Promotes weight loss and appetite suppression
• Can be used alone or with other diabetes medications
• Once-daily dosing for convenience
• Improves overall glycemic control

Side Effects

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Dyspepsia
• Headache
• Dizziness
• Injection site reactions
• Hypoglycemia (when used with sulfonylurea/insulin)
• Pancreatitis (rare but serious)
• Thyroid C-cell tumors (seen in rodents, human relevance unknown)

Safety Measures

• Alcohol - Alcohol can affect blood sugar levels and may increase the risk of hypoglycemia. Use with caution.
• Pregnancy - Not recommended during pregnancy. Consult a doctor; alternative treatments may be necessary.
• Breastfeeding - Not recommended during breastfeeding due to unknown excretion into human milk.
• Liver - Use with caution in patients with severe hepatic impairment; limited experience in this population.
• Kidney - Use with caution in patients with severe renal impairment or end-stage renal disease.
• Lung - No specific contraindications for lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.